Eline van der Burg

3.0k citations

19 papers · 1.7k indexed · 1 hit paper · h-index 13

Oncology top 2%
- PARP inhibition in cancer therapy 5
- Cancer Cells and Metastasis 5
Reproductive Medicine top 5%
Cancer Research top 10%
- Cancer Genomics and Diagnostics 3
Molecular Biology top 10%
- DNA Repair Mechanisms 6
- Wnt/β-catenin signaling in development and cancer 3
- Genomics and Chromatin Dynamics 3
- CRISPR and Genetic Engineering 2
Genetics top 5%
- BRCA gene mutations in cancer 5

Co-authors: Jos Jonkers Patrick W.B. Derksen Mark J. O’Connor Michiel de Bruin Niall M.B. Martin Alan Lau Ariena Kersbergen Piet Borst
Cited by: Oncology Reproductive Medicine Cancer Research
Journals: Proceedings of the National Academy of Sciences (1 paper)Nature Communications (3 papers)Nature Genetics (1 paper)
Partner nations: Netherlands United Kingdom Germany

In The Last Decade

Eline van der Burg

18 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Eline van der Burg

Since Specialization

Citations

This map shows the geographic impact of Eline van der Burg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eline van der Burg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eline van der Burg more than expected).

Fields of papers citing papers by Eline van der Burg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eline van der Burg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eline van der Burg. The network helps show where Eline van der Burg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eline van der Burg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eline van der Burg Line = papers co-authored together Eline van der Burg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 Cancer Research ·Julia Yemelyanenko,Jinhyuk Bhin,Eline van der Burg,Anne Paulien Drenth,J. Lee,Catrin Lutz,Lea Dörner,Ellen Wientjens,Sjoerd Klarenbeek,Ji-Ying Song,Hyeonjin Moon,Stefano Annunziato,Natalie Proost,Bjørn Siteur,Jeffrey S. Ross,Marieke van de Ven,Olaf van Tellingen,Shridar Ganesan,(unknown),Daniel Zingg,Jos Jonkers	2025	0
2	FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks Science Advances ·Abdelghani Mazouzi,Sarah C. Moser,Federico Abascal,Bram van den Broek,Martin Del Castillo Velasco‐Herrera,Ingrid van der Heijden,Maarten L. Hekkelman,Anne Paulien Drenth,Eline van der Burg,Lona J. Kroese,Kees Jalink,David J. Adams,Jos Jonkers,Thijn R. Brummelkamp	2023	10
3	CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer Nature Communications ·Julia M. Houthuijzen,Roebi de Bruijn,Eline van der Burg,Anne Paulien Drenth,Ellen Wientjens,Tamara Filipovic,Esme Bullock,Chiara Svetlana Brambillasca,Emilia M. Pulver,Marja Nieuwland,Iris de Rink,Frank van Diepen,Sjoerd Klarenbeek,Ron Kerkhoven,Valerie G. Brunton,Colinda L. G. J. Scheele,Mirjam C. Boelens,Jos Jonkers	2023	63
4	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms Cancer Research ·Koen Schipper,Anne Paulien Drenth,Eline van der Burg,Samuel Cornelissen,Sjoerd Klarenbeek,Micha Nethe,Jos Jonkers	2020	7
5	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer Nature Communications ·Stefano Annunziato,Julian R. de Ruiter,Linda Henneman,Chiara Svetlana Brambillasca,Catrin Lutz,François Vaillant,Federica Ferrante,Anne Paulien Drenth,Eline van der Burg,Bjørn Siteur,Bas van Gerwen,Roebi de Bruijn,Martine H. van Miltenburg,Ivo J. Huijbers,Marieke van de Ven,Jane E. Visvader,Geoffrey J. Lindeman,Lodewyk F.A. Wessels,Jos Jonkers	2019	54
6	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin Nature Communications ·Koen Schipper,Daniëlle Seinstra,Anne Paulien Drenth,Eline van der Burg,Veronika Ramovš,Arnoud Sonnenberg,Jacco van Rheenen,Micha Nethe,Jos Jonkers	2019	23
7	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development Genes & Development ·Lisette M. Cornelissen,Anne Paulien Drenth,Eline van der Burg,Roebi de Bruijn,Colin E.J. Pritchard,Ivo J. Huijbers,Wilbert Zwart,Jos Jonkers	2019	37
8	BRCA1‐associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling The Journal of Pathology ·Marieke van de Ven,Xiaoling Liu,Eline van der Burg,Sjoerd Klarenbeek,Xanthippi Alexi,Wilbert Zwart,Fred A. Dijcks,Peter Bouwman,Jos Jonkers	2018	9
9	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma Nature Genetics ·Sjors M. Kas,Julian R. de Ruiter,Koen Schipper,Stefano Annunziato,Eva Schut,Sjoerd Klarenbeek,Anne Paulien Drenth,Eline van der Burg,Christiaan Klijn,Jelle J. ten Hoeve,David J. Adams,Marco J. Koudijs,Jelle Wesseling,Micha Nethe,Lodewyk F.A. Wessels,Jos Jonkers	2017	55
10	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma Cell Reports ·Mirjam C. Boelens,Micha Nethe,Sjoerd Klarenbeek,Julian R. de Ruiter,Eva Schut,Nicola Bonzanni,Amber L. Zeeman,Ellen Wientjens,Eline van der Burg,Lodewyk F.A. Wessels,Renée van Amerongen,Jos Jonkers	2016	37
11	EZH2 inhibition sensitizes BRCA1-deficient breast tumors to the PI3K inhibitor BKM120 Geburtshilfe und Frauenheilkunde ·Julian Puppe,Marieke van de Ven,Eline van der Burg,Ute Boon,Olaf van Tellingen,Peter Bouwman,Peter Mallmann,Rita K. Schmutzler,Maarten van Lohuizen,J. Jonkers	2016	1
12	Prophylactic window therapy with the clinical poly(ADP‐ribose) polymerase inhibitor olaparib delays BRCA1‐deficient mammary tumour formation in mice The Journal of Pathology ·Marieke van de Ven,Eline van der Burg,Hanneke van der Gulden,Sjoerd Klarenbeek,Peter Bouwman,Jos Jonkers	2016	3
13	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation International Journal of Cancer ·Floris H. Groenendijk,Wouter W. Mellema,Eline van der Burg,Eva Schut,Michael Hauptmann,Hugo M. Horlings,Stefan M. Willems,Michel M. van den Heuvel,Jos Jonkers,Egbert F. Smit,René Bernards	2014	61
14	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice Disease Models & Mechanisms ·Patrick W.B. Derksen,Tanya M. Braumuller,Eline van der Burg,Marten Hornsveld,Elly Mesman,Jelle Wesseling,Paul Krimpenfort,Jos Jonkers	2011	101
15	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan Cancer Research ·Serge A.L. Zander,Ariena Kersbergen,Eline van der Burg,Niels de Water,Olaf van Tellingen,Sjöfn Gunnarsdottir,Janneke E. Jaspers,Marina Pajic,Anders O.H. Nygren,Jos Jonkers,Piet Borst,Sven Rottenberg	2010	66
16	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clinical Cancer Research ·Bastiaan Evers,Eva Schut,Eline van der Burg,Tanya M. Braumuller,David A. Egan,Henne Holstege,Pauline Edser,David J. Adams,Richard Wade‐Martins,Peter Bouwman,Jos Jonkers	2009	66
17	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer Cancer Research ·Marina Pajic,Jayasree K. Iyer,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Jos Jonkers,Piet Borst,Sven Rottenberg	2009	77
18	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsbreakdown → Proceedings of the National Academy of Sciences ·Sven Rottenberg,Janneke E. Jaspers,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Serge A.L. Zander,Patrick W.B. Derksen,Michiel de Bruin,John Zevenhoven,Alan Lau,Robert Boulter,Aaron Cranston,Mark J. O’Connor,Niall M.B. Martin,Piet Borst,Jos Jonkers	2008	762
19	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clinical Cancer Research ·Bastiaan Evers,Rinske Drost,Eva Schut,Michiel de Bruin,Eline van der Burg,Patrick W.B. Derksen,Henne Holstege,Xiaoling Liu,Ellen van Drunen,H. Berna Beverloo,Graeme C.M. Smith,Niall M.B. Martin,Alan Lau,Mark J. O’Connor,Jos Jonkers	2008	259

About Eline van der Burg

Eline van der Burg is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 19 papers that have together received 1.7k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (6 papers), BRCA gene mutations in cancer (5 papers), PARP inhibition in cancer therapy (5 papers), Cancer Cells and Metastasis (5 papers), Cancer Genomics and Diagnostics (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers), Genomics and Chromatin Dynamics (3 papers) and CRISPR and Genetic Engineering (2 papers). The work is most often cited by research in Oncology (1.3k citations), Reproductive Medicine (152 citations) and Cancer Research (262 citations). Eline van der Burg has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Jos Jonkers, Patrick W.B. Derksen, Mark J. O’Connor, Michiel de Bruin, Niall M.B. Martin, Alan Lau, Ariena Kersbergen, Piet Borst, Anders O.H. Nygren and Sven Rottenberg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact